[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atyr Pharma Inc (ATYR)

Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,418
  • Shares Outstanding, K 98,051
  • Annual Sales, $ 190 K
  • Annual Income, $ -74,120 K
  • EBIT $ -79 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.66
  • Price/Sales 288.94
  • Price/Cash Flow N/A
  • Price/Book 0.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings $-0.14 on 03/05/26
  • Next Earnings Date 05/20/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 207.91% (+31.06%)
  • Historical Volatility 231.62%
  • IV Percentile 46%
  • IV Rank 12.11%
  • IV High 1,155.84% on 10/08/25
  • IV Low 77.30% on 06/16/25
  • Expected Move (DTE 33) 0.4080 (80.95%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 724
  • Volume Avg (30-Day) 1,084
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 52,729
  • Open Int (30-Day) 46,154
  • Expected Range 0.0960 to 0.9120

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.17
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) +22.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3950 +27.59%
on 05/13/26
1.0500 -52.00%
on 05/06/26
-0.3387 (-40.19%)
since 04/15/26
3-Month
0.3950 +27.59%
on 05/13/26
1.1100 -54.59%
on 02/19/26
-0.3899 (-43.62%)
since 02/13/26
52-Week
0.3950 +27.59%
on 05/13/26
7.2904 -93.09%
on 07/28/25
-2.4960 (-83.20%)
since 05/15/25

Most Recent Stories

More News
Atyr Pharma: Q1 Earnings Snapshot

Atyr Pharma: Q1 Earnings Snapshot

ATYR : 0.5040 (-9.98%)
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

  Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in...

ATYR : 0.5040 (-9.98%)
aTyr Pharma to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...

ATYR : 0.5040 (-9.98%)
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.President...

ATYR : 0.5040 (-9.98%)
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic,...

ATYR : 0.5040 (-9.98%)
Atyr Pharma: Q4 Earnings Snapshot

Atyr Pharma: Q4 Earnings Snapshot

ATYR : 0.5040 (-9.98%)
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.  Phase 2 EFZO-CONNECT™...

ATYR : 0.5040 (-9.98%)
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class...

ATYR : 0.5040 (-9.98%)
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...

ATYR : 0.5040 (-9.98%)
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb....

ATYR : 0.5040 (-9.98%)

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Key Turning Points

3rd Resistance Point 0.6456
2nd Resistance Point 0.6128
1st Resistance Point 0.5584
Last Price 0.5040
1st Support Level 0.4712
2nd Support Level 0.4384
3rd Support Level 0.3840

See More

52-Week High 7.2904
Fibonacci 61.8% 4.6564
Fibonacci 50% 3.8427
Fibonacci 38.2% 3.0290
Last Price 0.5040
52-Week Low 0.3950

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.